Cargando…

Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway

Lipotoxicity cardiomyopathy is the result of excessive accumulation and oxidation of toxic lipids in the heart. It is a major threat to patients with diabetes. Glucagon‐like peptide‐1 (GLP‐1) has aroused considerable interest as a novel therapeutic target for diabetes mellitus because it stimulates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Lujin, Wang, Ke, Wang, Wei, Wen, Zheng, Wang, Peihua, Liu, Lei, Wang, Dao Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052396/ https://www.ncbi.nlm.nih.gov/pubmed/29659121 http://dx.doi.org/10.1111/acel.12763

Ejemplares similares

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE(–/–) Mice
por: Liu, Fuqiang, et al.
Publicado: (2020)

PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1
por: Wang, Wei, et al.
Publicado: (2020)

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
por: Qiu, Zirui, et al.
Publicado: (2022)

The Role of Lipotoxicity in Smoke Cardiomyopathy
por: Santos, Priscila P., et al.
Publicado: (2014)

Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway
por: Tian, Xue, et al.
Publicado: (2022)

The Critical Role of Astragalus Polysaccharides for the Improvement of PPRAα-Mediated Lipotoxicity in Diabetic Cardiomyopathy
por: Chen, Wei, et al.
Publicado: (2012)

β-Lapachone Ameliorates Lipotoxic Cardiomyopathy in Acyl CoA Synthase Transgenic Mice
por: Jeong, Moon Hee, et al.
Publicado: (2014)

Endurance exercise resistance to lipotoxic cardiomyopathy is associated with cardiac NAD(+)/dSIR2/PGC-1α pathway activation in old Drosophila
por: Wen, Deng-Tai, et al.
Publicado: (2019)

Fatty old hearts: role of cardiac lipotoxicity in age-related cardiomyopathy
por: Drosatos, Konstantinos
Publicado: (2016)

CYP2J2 and Its Metabolites EETs Attenuate Insulin Resistance via Regulating Macrophage Polarization in Adipose Tissue
por: Dai, Meiyan, et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα
por: Yin, Zhongwei, et al.
Publicado: (2019)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
por: Tan, Tricia M., et al.
Publicado: (2013)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
por: Wang, Xu, et al.
Publicado: (2017)

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis
por: Wu, Lujin, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice
por: Zhu, Changliang, et al.
Publicado: (2021)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
por: Hong, Yeonhee, et al.
Publicado: (2019)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Huang, Chiang-Chi, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Agonists Protect Pancreatic β-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB
por: Cunha, Daniel A., et al.
Publicado: (2009)

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway
por: Liu, Jieyu, et al.
Publicado: (2013)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Bioactivity of a modified human Glucagon-like peptide-1
por: Xu, Fangfang, et al.
Publicado: (2017)

Nobiletin ameliorates high fat-induced disruptions in rhythmic glucagon-like peptide-1 secretion
por: Martchenko, Alexandre, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Bean Leaves Ameliorate Lipotoxicity in Fatty Liver Disease
por: Becerril-Campos, Adriana Araceli, et al.
Publicado: (2023)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
por: Wang, XingChun, et al.
Publicado: (2015)

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis
por: Zhang, Zhuo-Ya, et al.
Publicado: (2023)

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia
por: Chen, Fangzhe, et al.
Publicado: (2016)

Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress
por: Lin, Tsu-Kung, et al.
Publicado: (2021)

Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism
por: Zhang, Xiaoying, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_esko5uio8unko96nil3unrvqoe